Emerging Mass Tort Cases Attorneys Should Monitor in 2026

Mass tort litigation moves in waves, and 2026 has brought a distinct new set of dockets into focus alongside several established litigations that continue to develop as bellwether trials, settlement negotiations, and new plaintiff filings unfold. For personal injury firms deciding where to focus marketing dollars, intake capacity, and co-counsel relationships, understanding the current landscape of active and emerging mass tort litigation is essential, both to identify genuine opportunity and to avoid overcommitting to a docket that hasn't yet developed the evidentiary or plaintiff-pool strength to justify significant investment. This piece surveys the major categories of mass tort litigation attorneys should be watching, along with practical guidance on positioning a firm to participate responsibly in each.

Firm leaders reviewing this landscape should keep in mind that mass tort dockets rarely develop in a predictable, linear fashion. A category of litigation that appears to be gaining significant momentum can slow considerably if early bellwether trials produce disappointing results for plaintiffs, while a docket that initially seemed niche can expand rapidly once additional plaintiff firms and scientific evidence accumulate around it. This inherent unpredictability is exactly why disciplined, ongoing monitoring, rather than a one-time assessment made at the start of a year, matters so much for firms trying to allocate marketing and litigation resources wisely across a shifting landscape, and why the specific dockets highlighted here should be read as a current snapshot rather than a fixed, permanent list.

Pharmaceutical and Medical Device Litigation

Pharmaceutical mass torts remain one of the largest and most established categories of litigation, and several dockets have continued to develop significant momentum. GLP-1 medication litigation, tied to a class of drugs originally developed for diabetes and weight management, has drawn increasing attention as plaintiffs raise concerns about gastrointestinal complications and other adverse effects, with filings continuing to accumulate as more claimants come forward and scientific and regulatory review continues. Medical device litigation has also remained active, with claims involving implantable devices such as certain vascular access ports continuing through the discovery and bellwether trial process in various federal court coordination proceedings. Firms considering pharmaceutical or device litigation should pay close attention to how the underlying science is developing, since these cases often hinge heavily on expert testimony and regulatory findings that can shift a docket's overall viability.

The GLP-1 litigation in particular illustrates how quickly a pharmaceutical mass tort can scale once public awareness and marketing volume both increase, given how widely this class of medications has been prescribed in recent years relative to many earlier pharmaceutical mass torts that involved more narrowly prescribed drugs. Firms entering this space should expect an unusually large and geographically dispersed potential plaintiff pool, which changes some of the calculus around media mix and intake staffing compared to mass torts with a smaller, more concentrated claimant population tied to a specific product or medical procedure used less broadly across the general population.

Firms evaluating pharmaceutical litigation more broadly should also track how the underlying regulatory agency, typically the FDA in the case of medications and devices, has responded to safety signals associated with a given product, since formal regulatory action, such as a label change, a safety communication, or a recall, often serves as a meaningful inflection point that both strengthens a docket's litigation posture and increases public awareness, which in turn tends to increase both plaintiff inquiry volume and firm competition for those inquiries.

Environmental and Exposure-Based Claims

PFAS, the broad family of synthetic chemicals sometimes referred to as forever chemicals due to their environmental persistence, continues to generate significant litigation activity across multiple fronts, including claims tied to firefighting foam exposure, contaminated water systems, and consumer products manufactured with PFAS compounds. This litigation category is particularly complex because it spans multiple defendant industries and involves both personal injury claims from individuals with documented health effects and broader claims from municipalities and water districts dealing with contamination remediation costs. Firms entering PFAS-related litigation need a clear understanding of which specific exposure pathway and defendant category they're pursuing, since the science, evidence requirements, and settlement dynamics differ meaningfully across the various PFAS-related claim categories.

Firefighting foam litigation specifically has developed a substantial body of coordinated federal proceedings, with plaintiffs including firefighters, military personnel, and airport workers with documented occupational exposure to aqueous film-forming foam over extended periods. This subset of PFAS litigation tends to involve more straightforward exposure documentation than broader consumer or municipal water contamination claims, since occupational exposure records and employment history often provide clearer evidence of exposure duration and intensity than trying to reconstruct an individual's exposure through general environmental or consumer product contact over the years.

Municipal and water district claims represent a different track within PFAS litigation, generally pursued as claims for contamination remediation and infrastructure costs rather than individual personal injury claims, and firms considering this angle should understand that it typically involves an entirely different client base, government entities and utilities rather than individual injured plaintiffs, along with different damages theories centered on cleanup and infrastructure costs rather than personal injury and medical damages.

Social Media and Technology Platform Litigation

Litigation alleging that social media platform design features contribute to addiction and related mental health harms in adolescent users has continued to develop as a significant and closely watched mass tort category, with coordinated proceedings addressing claims against major platform operators. This litigation represents a newer frontier for mass tort practice, since it involves novel legal theories around product design and platform liability rather than the more established medical causation frameworks that dominate pharmaceutical litigation. Firms considering this space should understand that novel litigation theories often carry more uncertainty around eventual settlement value and timeline than more established mass tort categories, even when public and media attention is significant.

Intake for this category of litigation also differs meaningfully from more traditional mass tort intake, since claimants are often minors or young adults, meaning parents or guardians are frequently the ones initiating contact and firms need intake processes sensitive to the particular dynamics of representing claims involving minors, including additional documentation and consent considerations that don't arise in most other mass tort categories. Firms without prior experience handling claims involving minor plaintiffs should build or acquire this expertise deliberately before marketing heavily into this space, since the procedural requirements differ from standard adult plaintiff intake in ways that matter for both compliance and case quality.

Reproductive and Women's Health Device Litigation

Litigation involving certain intrauterine devices, including claims related to device fragmentation and removal complications, has continued to develop as manufacturers face coordinated proceedings addressing product liability and adequacy-of-warning claims. This category tends to require careful medical record review to establish a clear causal link between the device and the alleged injury, and firms handling these cases need intake processes capable of gathering detailed procedural and medical history from claimants early in the process to properly assess case strength before committing significant marketing or litigation resources.

This category of litigation also tends to draw a claimant population with a particularly strong emotional and personal connection to their case, given the nature of the medical complications involved, which means intake and case management staff benefit from training in sensitive, trauma-aware communication alongside the standard eligibility screening process. Firms that handle this kind of intake with genuine care and sensitivity, not just procedural efficiency, tend to build stronger client relationships and better client cooperation throughout what can be a lengthy litigation process.

Bard PowerPort and Vascular Access Device Litigation

Litigation involving certain implantable vascular access ports, used to provide long-term intravenous access for patients receiving chemotherapy and other regular infusion treatments, has continued through coordinated federal proceedings addressing claims that device fracture and migration caused serious internal injuries. This litigation illustrates a pattern common to medical device mass torts: claimants are often already dealing with a serious underlying medical condition that necessitated the device in the first place, which means attorneys need to carefully distinguish between complications attributable to the device itself and complications that might be more directly related to the patient's underlying illness or treatment.

This distinction matters considerably for case evaluation, since a claim's strength depends heavily on medical record documentation clearly linking the alleged device malfunction to the specific injury claimed, rather than a more general, harder-to-prove assertion that the device contributed to a broader decline in health that could plausibly have other contributing causes. Firms handling this type of litigation benefit from working closely with medical experts early in the case evaluation process, rather than waiting until formal discovery to assess causation strength, since early expert input can meaningfully sharpen which cases within a firm's intake pipeline deserve the most immediate attention and resources.

Talc and Consumer Product Litigation

Litigation involving talc-based consumer products and alleged links to certain cancers has continued as one of the longer-running mass tort categories, with ongoing bankruptcy proceedings and settlement negotiations affecting how and when claims in this docket ultimately resolve. This litigation illustrates a dynamic increasingly relevant across mass tort practice generally: a defendant's use of bankruptcy proceedings to address mass tort liability, which can significantly affect both the timeline and the eventual structure of compensation available to claimants, and attorneys handling these cases need to understand bankruptcy court dynamics alongside traditional tort litigation strategy.

Firms newer to mass tort practice should treat this docket's extended timeline as an instructive example of how long even a well-established, extensively litigated mass tort can take to fully resolve, tempering expectations for how quickly a newer docket might realistically move from initial filings to a global resolution.

• GLP-1 medication litigation tied to gastrointestinal and other adverse effect claims.
• PFAS exposure litigation spanning firefighting foam, water contamination, and consumer product claims.
• Social media platform design litigation tied to adolescent mental health and addiction claims.
• Medical device litigation involving implantable products and related complication claims.
• Ongoing developments in previously established dockets as bellwether trials and settlement talks progress.

How to Assess Whether a New Docket Is Worth Pursuing

Not every emerging mass tort headline translates into a viable practice opportunity, and firms need a disciplined framework for separating dockets with genuine litigation traction from those generating media attention without yet developing the scientific, regulatory, or judicial momentum that eventually drives settlement value. Key signals worth watching include whether an MDL, or multidistrict litigation coordination, has actually formed, since formal coordination signals that a federal judiciary panel has found enough common questions of fact across filed cases to justify centralized proceedings. Other useful signals include whether regulatory agencies have taken formal action related to the underlying product or exposure, whether early bellwether trials have occurred and what their outcomes suggest about the litigation's overall trajectory, and how many firms are already actively marketing for the docket, which affects both plaintiff acquisition cost and eventual settlement fund allocation dynamics.

Firms should also weigh the strength and independence of the underlying scientific literature supporting a claimed injury or exposure link, distinguishing between claims backed by peer-reviewed research and regulatory findings versus claims resting primarily on preliminary studies or anecdotal reports that haven't yet been substantiated through more rigorous scientific review. Litigation built on a thinner scientific foundation carries meaningfully more risk, both in terms of eventual case outcomes and in terms of how defense counsel will likely attack causation during litigation, and firms should factor this risk into how aggressively they market and how much they invest in a given docket relative to more scientifically established litigation.

Consulting with experienced mass tort co-counsel or industry publications that track MDL formations and settlement trends closely can help firms newer to a specific docket type calibrate their own assessment against more experienced perspectives, rather than relying solely on public news coverage, which often lags behind the actual state of the underlying litigation and can either overstate or understate a docket's genuine viability depending on how much media attention a particular case has attracted relative to its actual legal strength. A brief written assessment summarizing these signals for each docket under consideration also helps firm leadership make more consistent, better-documented decisions over time.

How Settlement Fund Structures Affect Case Value Expectations

When a mass tort docket eventually reaches a global settlement, compensation is typically distributed through a structured allocation process that weighs factors like injury severity, documented exposure duration, and specific damages criteria defined by a settlement matrix or special master's allocation protocol, rather than every claimant simply receiving an equal or individually negotiated amount. Understanding this structure matters for setting realistic client expectations early in a case, since clients sometimes arrive with expectations shaped by news coverage of the total settlement fund size without understanding that individual allocations depend heavily on where their specific case falls within the settlement's severity and documentation tiers.

Firms that explain this allocation process clearly to clients from the outset of representation, rather than leaving it as a surprise once a settlement is finally reached, tend to manage client expectations and satisfaction far better than firms that let clients assume a straightforward, evenly distributed payout structure. This is particularly important in dockets with a very large plaintiff pool, where the difference between a well-documented, high-severity claim and a more marginal claim can result in a substantial difference in eventual individual compensation, even though both claims technically fall within the same overall litigation.

Positioning Intake for Multiple Concurrent Dockets

Firms actively marketing across several mass tort dockets simultaneously face a real operational challenge: each docket typically has its own specific qualification criteria, required documentation, and intake screening questions, and applying a generic intake process across all of them risks either improperly disqualifying viable claimants or, worse, signing clients who don't actually meet a given docket's eligibility criteria once deeper medical record review occurs. Building docket-specific intake scripts and qualification checklists, and training intake staff to apply the correct criteria for each active campaign, helps firms avoid this kind of costly cross-contamination between different litigation categories.

Firms running multiple concurrent campaigns should also invest in intake technology capable of routing and tagging leads by docket automatically at the point of capture, since manual routing becomes increasingly error-prone as the number of active campaigns grows. A misrouted lead, one directed to the wrong docket-specific screening script, can result in a claimant being asked entirely irrelevant qualification questions, creating a poor first impression and increasing the likelihood that an otherwise viable claimant disengages before qualification is even completed.

Weighing Timeline Expectations Realistically

Mass tort litigation timelines are notoriously long, often stretching several years from initial filings through eventual settlement or trial resolution, and firms need to set realistic internal expectations, and realistic expectations with signed clients, about how long a given docket is likely to take to resolve. Newer dockets in particular carry significant timeline uncertainty, since the path from initial filings to MDL formation, through discovery and bellwether trials, to eventual global settlement negotiations, can vary enormously depending on how contested the underlying liability and causation questions turn out to be.

Setting these expectations clearly with clients at the outset of representation, rather than allowing an implicit assumption that a mass tort case will resolve on a similar timeline to a typical individual personal injury claim, protects both the client relationship and the firm's reputation over the life of a lengthy litigation. Firms that build clear, periodic client communication practices into their mass tort case management, providing status updates even when there's no major development to report, tend to retain client trust and cooperation far better over a multi-year litigation than firms that go quiet for extended stretches between major milestones.

Watching for Regulatory and Legislative Catalysts

Beyond the litigation itself, firms tracking mass tort dockets should watch for regulatory and legislative catalysts that can meaningfully shift a docket's trajectory with little advance warning. A sudden FDA safety communication, an EPA regulatory action on an environmental contaminant, or a state legislature considering product liability reform all have the potential to accelerate or complicate an existing docket's momentum. Firms with staff or counsel dedicated to monitoring these regulatory and legislative developments, rather than relying solely on litigation news coverage, often gain a meaningful head start on adjusting marketing and intake strategy before competitors catch up to the same development.

This kind of regulatory monitoring is particularly valuable for firms trying to identify genuinely new, not-yet-crowded docket opportunities, since the earliest, most reliable signals of an emerging mass tort often come from regulatory filings and safety communications well before mainstream media coverage or plaintiff firm marketing activity picks up on the underlying issue.

Building Co-Counsel Relationships for Docket Diversification

Given the uncertainty inherent in any single mass tort docket's eventual outcome, many firms diversify their mass tort practice across multiple litigation categories rather than concentrating entirely on one docket, often through co-counsel relationships that let a firm participate in a docket's litigation and marketing without bearing the full cost and risk of leading that litigation independently. These relationships can be particularly valuable for firms newer to mass tort practice, providing both litigation experience-sharing and a way to spread client acquisition costs across a partner firm's existing marketing infrastructure rather than building that capability entirely from scratch.

Diversification across multiple dockets also provides a natural hedge against the timeline and outcome uncertainty inherent in any single mass tort litigation, since a disappointing bellwether outcome or an unexpectedly narrow eventual settlement fund in one docket can be offset by stronger performance in another, provided a firm has genuinely diversified its caseload rather than concentrating disproportionately in a single litigation category regardless of how promising that single docket appeared at the outset.

Staying Current as the Landscape Shifts

Given how quickly the mass tort landscape can shift, firms benefit from building an ongoing monitoring habit rather than treating docket assessment as a once-a-year exercise. This might include regular review of MDL panel filings and orders, subscribing to legal industry publications that track mass tort developments, and maintaining relationships with co-counsel firms and vendors who often have early visibility into emerging litigation trends before they reach mainstream legal media coverage. Firms that build this kind of ongoing awareness into their regular operating rhythm are better positioned to move early on genuinely promising new dockets, and to pull back early from dockets that are losing momentum, than firms that only reassess their mass tort strategy sporadically.

The mass tort landscape in 2026 continues to reflect the same underlying pattern that has defined this area of litigation for years: a mix of well-established dockets working through their later litigation stages alongside genuinely new claim categories still building the evidentiary and regulatory momentum that will determine their eventual scale. Firms that track these developments closely, apply a disciplined framework for assessing new dockets, and build intake and co-counsel infrastructure capable of handling multiple concurrent litigations will be best positioned to participate profitably and responsibly as this landscape continues to shift throughout the year.